Read This Before You Think About Selling Sequenom

Before you go, we thought you'd like these...
Before you go close icon

Should you sell Sequenom (NAS: SQNM) today?

The decision to sell a stock you've researched and followed for months or years is never easy. But if you fall in love with your stock holdings, you risk becoming vulnerable to confirmation bias -- listening only to information that supports your theories, and rejecting any contradictions.

In 2004, longtime Fool Bill Mann called confirmation bias one of the most dangerous components of investing. This warning has helped my own investing throughout the Great Recession. Now I want to help you identify potential sell signs on popular stocks within our 4-million-strong Fool.com community.

Today I'm laser-focused on Sequenom, ready to evaluate its price, valuation, margins, and liquidity. Let's get started!

Don't sell on price
Over the past 12 months, Sequenom is down 2.3% versus an S&P 500 return of 9.1%.  Investors in Sequenom are no doubt disappointed with their returns, but is now the time to cut and run? Not necessarily. Short-term underperformance alone is not a sell sign. The market may be missing the critical element of your Sequenom investing thesis. For historical context, let's compare Sequenom's recent price with its 52-week and five-year highs. I've also included a few other businesses in the same industry or a related one.

Company

Recent Price

52-Week High

5-Year High

Sequenom$5.56$8.71$29.10
Myriad Genetics (NAS: MYGN) $18.59$25.89$47.10
DexCom (NAS: DXCM) $11.14$16.91$16.90
Luminex (NAS: LMNX) $22.04$24.70$27.00

Source: Capital IQ, a division of Standard & Poor's.

As you can see, Sequenom is down from its 52-week high. If you bought near the peak, now's the time to think back to why you bought it in the first place. If your reasons still hold true, you shouldn't sell based on this information alone.

Potential sell signs
First, let's look at the gross margins trend, which represents the amount of profit a company makes for each $1 in sales, after deducting all costs directly related to that sale. A deteriorating gross margin over time can indicate that competition has forced the company to lower prices, that it can't control costs, or that its whole industry's facing tough times. Here is Sequenom's gross margin over the past five years.

anImage

Source: Capital IQ, a division of Standard & Poor's.

Sequenom is having no trouble maintaining its gross margin, which tends to dictate a company's overall profitability. This is solid news; however, Sequenom investors need to keep an eye on this over the coming quarters. If margins begin to dip, you'll want to know why.

Next, let's explore what other investors think about Sequenom. We love the contrarian view here at Fool.com, but we don't mind cheating off our neighbors every once in a while. For this portion of our research, we'll examine two metrics: Motley Fool CAPS ratings and short interest. The former tells us how Fool.com's 170,000-strong community of individual analysts rates the stock, and the latter shows what proportion of investors is betting that the stock will fall. I'm including other peer companies once again for context.

Company

CAPS Rating

Short Interest (% of Float)

Sequenom321.6
Myriad Genetics46.4
DexCom19.3
Luminex25.5

Source: Capital IQ, a division of Standard & Poor's.

The Fool community is in the middle of the road on Sequenom. We typically like to see our stocks rated at four or five stars. Anything below that level is a less-than-bullish indicator. I highly recommend you visit Sequenom's stock-pitch page to see the verbatim reasons behind the ratings.

Here, short interest is at a high 21.6%. A number like typically indicates that large institutional investors are betting against the stock.

Now, let's study Sequenom's debt situation, with a little help from the debt-to-equity ratio. This metric tells us how much debt the company's taken on, relative to its overall capital structure.

anImage

Source: Capital IQ, a division of Standard & Poor's.

Sequenom has been taking on some very minor debt over the past five years.  Even with increasing total equity over the same time period, debt-to-equity has increased. Based on the trend alone, that's a bad sign, though I wouldn't be overly concerned given the small amount. I consider a debt-to-equity ratio below 50% to be healthy, though the number varies by industry. Sequenom is currently below this level, at 1.1%.

The last metric I like to look at is the current ratio, which lets investors judge a company's short-term liquidity. If Sequenom had to convert its current assets to cash in one year, how many times over could it cover its current liabilities? As of the last filing, Sequenom has a current ratio of 8.1. This is a healthy sign. I like to see companies with current ratios equal to or greater than 1.5.

Finally, it's highly beneficial to determine whether Sequenom belongs in your portfolio -- and to know how many similar businesses already occupy your stable of investments. If you haven't already, be sure to put your tickers into Fool.com's free portfolio tracker, My Watchlist. You can get started right away by adding Sequenom.

The final recap

anImage

Sequenom has failed three of the quick tests that would make it a sell. Does that mean you should sell your Sequenom shares today? Not necessarily, but keep your eye on these trends over the coming quarters.

To do that, I strongly recommend adding Sequenom to My Watchlist to help you keep track of all of our ongoing coverage of the company.

At the time this article was published Jeremy Phillipsowns no shares of the companies mentioned. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners